Polyrizon to Moving Forward with Expected 2025 Clinical Trial and Previously Announced Manufacturing Agreement for its PL-14 Allergy Blocker

December 18, 2024

DENVER, Colo., Dec 18, 2024 (247marketnews.com)- Polyrizon (NASDAQ:PLRZ) is one of the morning’s most active listings following its reiteration of previously announced news that it entered into a manufacturing agreement with Eurofins CDMO Amatsiaquitaine, which will supply Clinical Trial Material (CTM) for Polyrizon’s PL-14 allergy blocker, in preparation for a clinical trial that is expected to commence in 2025.

Tomer Izraeli, Polyrizon’s CEO previously stated, “We are pleased to have established this partnership with Eurofins CDMO Amatsiaquitaine S.A.S, which strengthens our preparation efforts for the upcoming PL-14 clinical trial. We believe that this collaboration marks a significant milestone in our journey toward providing effective allergy protection solutions to patients.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (PLRZ)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.